

CORYNEBACTERIUM STRIATUM (CS) - IMPLICATIONS IN THE PATHOGENESIS OF VENTILATOR-ASSOCIATED PNEUMONIA (VAP). LOCAL PECULIARITIES OF EPIDEMIOLOGY AND TREATMENT

S. NEGOIȚĂ¹, MADALINA DUȚU², RELY MANOLESCU³, D. CORNECI⁴, L. AZAMFIREI⁵

^{1,2,3,4} Elias Emergency University Hospital Bucharest, ² Emergency University Hospital, Tg. Mures

Keywords:

Corynebacterium striatum, ventilator-associated pneumonia

Abstract: Nondiphtherial corynebacteria may induce alone or along with other germs, severe respiratory infections in critically ill patients. We conducted a retrospective study over a period of one year, which included patients diagnosed with VAP using CDC diagnostic criterion. Patients were divided into three groups: group A comprising 12 patients who developed infection only with Cs, group B comprising 16 patients with VAP produced by Cs and other pathogens and group C comprising 127 patients as reference group. VAP incidence with Cs was 11.2% of all infections, 42% representing single infection, the others co infections or super infections with Cs. Cs infection was associated statistically significant ($p < 0.05$) with severe neurological pathology. VAP mortality induced by this germ was 58%, significantly higher value compared to local mortality in VAP (35%). Evolution was more severe and increased mortality in cases of co infection/super infection particularly in combination with *Acinetobacter* spp. If the initially the pathogen was sensitive to antibiotics, further the spectrum of resistance narrowed, germ became resistant to carbapenems and quinolones. Evolution of pulmonary infections due to Cs is severe because of its high pathogenicity, acquired microbial resistance to carbapenems and immunological profile of the critically ill patient.

Cuvinte cheie:
Corynebacterium striatum, pneumonia asociata ventilatiei mecanice

Rezumat: *Corynebacteriile nondifteroide pot produce ca o agen patogeni sau copatogeni, infecții severe respiratorii la pacienții critici. Am desfășurat un studiu retrospectiv pe o perioadă de un an, ce a inclus pacienți diagnosticați cu VAP, utilizând criteriile de diagnostic CDC. Pacienții au fost împărțiți în trei loturi: lotul A cuprinzând 12 pacienți ce au dezvoltat monoinfecție cu Cs, lotul B cuprinzând 16 pacienți cu VAP de etiologie plurimicrobiană (Cs și alți patogeni), respectiv lotul C cuprinzând 127 pacienți, ca lot de referință. Incidența VAP cu Cs a reprezentat 11,2 % din totalul infecțiilor, 42% reprezentând primoinfecții cu Cs restul coinfecții sau suprainfecții. Infecția cu Cs s-a asociat semnificativ statistic, ($p < 0.05$) cu patologia neurologică severă. Mortalitatea prin VAP cu Cs a fost de 58%, valoare semnificativ mai ridicată comparativ cu mortalitatea locală prin VAP (35%). Evoluția a fost mai severă și rata mortalității crescute în cazurile de coinfecție/suprainfecție în special în asociere cu *Acinetobacter* spp. Dacă inițial agentul patogen a fost sensibil la antibioterapie, ulterior spectrul de rezistență s-a îngustat, germenul devenind rezistent la carbapeneme și chinolone. Evoluția infecțiilor pulmonare cu Cs e severă din cauza patogenității ridicate a germenului, dobândirii rezistenței microbiene la carbapeneme și al profilului imunologic al pacientului critic.*

INTRODUCTION

Ventilator-associated pneumonia (VAP) is a form of nosocomial pneumonia that develops 48 hours or longer after mechanical ventilation (MV). It is an inflammation of lung parenchyma induced by germs that are not present at the start of MV. VAP is a major cause of infections in ICU leading to increased morbidity, mortality and cost of care. Since 2007 the occurrence of this infection in ICU is no longer considered an accident but medical negligence. Nondiphtherial corynebacteria normally colonize the skin and mucous membranes. They are usually not involved in the pathology of VAP but may induce as pathogens or co-pathogens severe respiratory infections in critically ill patients. (1) Due to increasing need for invasive mechanical ventilation in ICU departments, the implications of new pathogens are becoming very important.

THE AIM OF THE STUDY

The report consisted of Cs as a possible pathogen of VAP, in establishing the infection characteristics, the epidemiological and clinical antibiotics resistance profile in ICU

Department Elias and determining factors that influence the microbial resistance to antibiotics of Cs.

MATERIAL AND METHOD

We performed a retrospective study conducted over a period of 12 months (01.03.2010 - 31.03.2011) on 156 patients from ICU Department Elias who developed VAP (different microbial etiologies). As the VAP diagnostic criteria we used CDC recommendations (using clinical, radiological and microbiological criteria) (2). Exclusion criteria were: presence of pulmonary infectious pathology at admission time, extreme ages (patients under 18 years and over 75 years), and presence of severe lung disease in personal history. Depending on the occurrence of *Corynebacterium striatum* infection patients were divided into 3 groups: group A (12 patients) – infection only with Cs, group B (16 patients) - coinfection/superinfection with Cs and group C (127 patients) - patients who developed VAP with common germs involved in this pathology. Consignments are comparable in terms of disease severity (APACHE score, SOFA score) and we have excluded patients who died from

¹Corresponding Author: S. Negoită, Elias Emergency University Hospital Bucharest, Romania; e-mail: silviusneg@gmail.com; tel +40- 0722415575
Article received on 28.12.2010 and accepted for publication on 11.04.2011
ACTA MEDICA TRANSILVANICA June 2011; 2(2)237-238


CLINICAL ASPECTS

others causes that lung infection. Groups A and B are statistically comparable, and group C was used as a reference system. We studied the incidence, mortality, the correlation with associated pathology, duration of mechanical ventilation, microbial resistance and its variation during the study.

RESULTS


The incidence of VAP with Cs was 11.2% of all ventilator-induced pneumonia, 42% representing single infection with Cs the others co infections or super infections. Diagnosed with early onset of VAP were 28% of patients and others with late onset of VAP. Cs infection was associated more often, statistically significant ($p < 0.05$) with severe neurological pathology. (Figure 1)

Figure no. 1. VAP presence linked to medical personal history



VAP induced by Cs mortality was 58%, significantly higher value compared to local mortality in VAP (35%). Evolution was more severe and increased mortality was reported in cases of co infection / super infection particularly in combination with *Acinetobacter* spp, compared with single infection, but without statistical significance. (Figure 2)

Figure no. 2. Mortality rate variation with germs involved




Mean length of mechanical ventilation was 15.8 days sensitive higher than group C (12.7 days), more patients requiring tracheotomy. If the pathogen was initially sensitive to carbapenems, quinolones, macrolides and aminoglycosides, further narrowed the spectrum of resistance, the species becoming resistant to carbapenems and quinolones.

DISCUSSION

Local epidemiological profile, resulting from these study reassembly microbiological reports in the medical literature worldwide. Most patients developed late onset of VAP, which leads to a more severe evolution of disease. Source of infection, although it is difficult to detect clearly is likely to be neurological intensive care unit, especially the first light of immunological and clinical characteristics of these patients. The method of transmission of this specific infection was from patient to patient. (3) That why we insist to apply all the VAP prevention measures (which have proven to be effective only together). Therapeutic approach, especially antimicrobial

therapy, was based on the principles of treatment of a severe infection in ICU and specific characteristics of Cs. We mainly used three classes of antibiotics: aminoglycosides, fluoroquinolones and carbapenems. There is retained sensitivity to aminoglycosides, proven sensitivity since the first reports of the pathogen Cs (Figure 3). Could be a little surprising the outbreak of resistance to carbapenems. There is a global trend of increasing resistance to carbapenems. Metallo- β -lactamases (VIM, IMP, and SIM) confer resistance to all β -lactams except Aztreonam. The most common β -lactamase with carbapenemase activity is CHDL and is likely to occur with Cs.

Figure no. 3. Antibiotics sensitivity



CONCLUSIONS

In recent years there is an emergence of opportunistic agents in VAP pathology, along with "traditional" microbial species. Pulmonary infection with Cs was associated more frequently in patients with severe neurological disease in a significant percent ($p < 0.05$). VAP with Cs causes a high mortality rate especially in combination with *Acinetobacter* spp. This opportunistic infection progresses to resistance to carbapenems and fluoroquinolones

BIBLIOGRAPHY

- Nosocomial Outbreak of *Corynebacterium striatum* Infection in Patients with Chronic Obstructive Pulmonary Disease, Feliu Renom,1* Margarita Garau,2 Mateu Rubí,1 Ferran Ramis,1 Antònia Galmés,3 and Joan B. Soriano4, Journal of Clinical Microbiology, June 2007, p. 2064-2067, Vol. 45, No. 6 0095-1137 /07/ \$08.00+0 doi: 10.1128/JCM.00152-07
- Ventilator-Associated Pneumonia: Diagnosis, Treatment, and Prevention, Steven M. Koenig and Jonathon D. Truwit* Pulmonary and Critical Care Medicine, University of Virginia, Charlottesville, Virginia 22908-Clin Microbiol Rev. 2006 October; 19(4): 637-657.
- Patient-to-Patient Spread of a Single Strain of *Corynebacterium striatum* Causing Infections in a Surgical Intensive Care Unit
- Afke H. Brandenburg, Alex van Belkum, Cindy van Pelt, Hajo A. Bruining, Journal of Clinical Microbiology, Sept. 1996, p. 2089-2094 Vol. 34, No. 9 0095-1137/96/\$04.0010
- Carbapenemase-producing *Acinetobacter* spp. in Kyoto University Hospital, Japan: the occurrence of metallo-beta-lactamases
- M. Yamamoto*, K. Yasuma, Y. Matsumura, A. Matsushima, M. Nagao, Y. Ito, S. Takakura, S. Ichiyama (Kyoto, JP)